Sofinnova closes €82m fund to create medtech companies
MD Start IV plans to launch six to eight ventures across Europe and the US over five years.
Sofinnova Partners has reached an €82 million final close for Sofinnova MD Start IV, its latest fund dedicated to creating medical technology companies. Announced on 28 September, the oversubscribed fund plans to launch six to eight ventures across Europe and the US over the next five years.
The strategy combines financing with hands-on company building, bringing together clinicians, scientists and engineers from inception. MD Start IV will support its ventures through clinical and operational milestones as technologies move toward patient use.
Use of funds
Create six to eight medtech companies across Europe and the US over five years
Support clinical and operational development